Table 1.
Patients with NIHSS < 8 stratified according to reperfusion success (TICI0-2a vs TICI2b/3)
| NIHSS < 8, N = 193 | TICI0-3 (N = 193) | TICI0-2a (N = 32) | TICI2b/3(N = 161) | P value |
|---|---|---|---|---|
| Age (years) | 66.7 + /− 14.6 | 68.2 + /− 13.1 | 69.95 + /−14.9 | 0.503 |
| Sex, female | 55.4% (107/193) | 53.1% (17/32) | 55.9% (90/161) | 0.846 |
| Admission NIHSS | 5 (IQR 4–6) | 5 (IQR 3–6) | 5 (IQR 4–6) | 0.777 |
| In-hospital stroke | 1.6% (3) | 0.0% (0/32) | 1.9% (3/161) | > 0.999 |
| Transfer | 36.5% (70/192) | 38.7% (12/31) | 36.0% (58/161) | 0.839 |
| Witnessed symptom-onset/last-seen well to admission (min, N = 178) | 148 (IQR 85–282) | 201 (IQR 79–282, N = 29) | 146 (IQR 87–285, N = 149) | 0.769 |
| Witnessed symptom-onset/last-seen well to groin puncture (min, N = 162) | 257 (IQR 196–393) | 295 (225–455, N = 26) | 250 (195–370, N = 136) | 0.248 |
| Admission Imaging, MRI (N = 191) | 57.6% (110/191) | 50.0% (16/32) | 59.1% (94/159) | 0.433 |
| IVT | 39.9% (77/193) | 31.3% (10/32) | 41.6% (67/161) | 0.326 |
| Risk factors | ||||
| Smoking (N = 191) | 28.8% (55/191) | 18.8% (6/32) | 30.8% (49/159) | 0.203 |
| Hypertension (N = 193) | 60.1% (116/193) | 56.3% (18/32) | 60.9% (98/161) | 0.694 |
| Dyslipidemia (N = 192) | 56.3% (108/192) | 51.6% (16/31) | 57.1% (92/161) | 0.693 |
| Previous CVE (N = 191) | 12.6% (24/191) | 3.1% (1/32) | 14.5% (23/159) | 0.086 |
| Diabetes (N = 193) | 13.5% (26/193) | 21.9% (7/32) | 11.8% (19/161) | 0.154 |
| Occlusion site | 0.203 | |||
| iICA | 2.1% (4/193) | 3.1% (1/32) | 1.9% (3/161) | |
| Carotid-T/L | 6.2% (12/193) | 12.5% (4/32) | 5.0% (8/161) | |
| M1 | 58.5% (113/193) | 46.9% (15/32) | 60.9% (98/161) | |
| M2 | 33.2% (64/193) | 37.5% (12/32) | 32.3% (52/161) | |
| Extracranial–intracranial tandem occlusion | 15.5% (30/193) | 21.9% (7/32) | 14.3% (23/161) | 0.290 |
| Underlying cervical dissection | 5.2% (10/193) | 6.3% (2/32) | 5.0% (8/161) | 0.673 |
| TOAST (N = 192) | 0.242 | |||
| Large-artery | 9.4% (18/192) | 15.6% (5/32) | 8.1% (13/160) | |
| Cardioembolism | 41.1% (79/192) | 28.1% (9/32) | 43.8% (70/160) | |
| Other | 8.9% (17/192) | 12.5% (4/32) | 8.1% (13/160) | |
| Unknown | 40.6% (78/192) | 43.8% (14/32) | 50.0% (64/160) | |
| Outcome | ||||
| mRS 0–1 | 45.1% (87/193) | 21.9% (7/32) | 49.7% (80/161) | 0.006† |
| mRS 0–2 | 65.8% (127/193) | 37.5% (12/32) | 71.4% (115/161) | < 0.001† |
| Non-hemorrhagic neurological worsening (N = 152) | 13.8% (21/152) | 38.1% (8/21) | 9.9% (13/131) | 0.002† |
| Mortality | 16.1% (31/193) | 28.1% (9/32) | 13.7% (22/161) | 0.062 |
| sICH (N = 192) | 4.2% (8/192) | 9.4% (3/32) | 3.1% (5/160) | 0.131 |
NIHSS National Institute of Health Stroke Scale, TICI Thrombolysis in Cerebral Infarction, IVT intravenous thrombolysis, CVE cerebrovascular event, iICA intracranial ICA, TOAST Trial of ORG 10,172 in Acute Stroke Treatment, mRS modified Rankin Scale, IQR interquartile range
†P < 0.01